<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04096742</url>
  </required_header>
  <id_info>
    <org_study_id>Altreno-2019-01</org_study_id>
    <nct_id>NCT04096742</nct_id>
  </id_info>
  <brief_title>Altreno for Chest Rejuvenation</brief_title>
  <official_title>A Prospective, Randomized, Double-blind, Vehicle-controlled Study Evaluating the Efficacy, Safety and Patient Satisfaction of Tretinoin 0.05% Lotion (Altreno) for Chest Rejuvenation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Goldman, Butterwick, Fitzpatrick and Groff</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bausch Health Americas, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Goldman, Butterwick, Fitzpatrick and Groff</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, prospective, double-blind, randomized, vehicle-controlled study to&#xD;
      evaluate the efficacy, safety and patient satisfaction of tretinoin 0.05% lotion (Altreno)&#xD;
      for chest rejuvenation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 6, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a single-center, prospective, double-blind, randomized, vehicle-controlled study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Skin Quality</measure>
    <time_frame>Baseline through Month 6</time_frame>
    <description>Nine-point scale to assess skin quality for the appearance of crepiness, coarse lines/wrinkles, skin texture, and skin tone evenness</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigator Assessment-Fabi-Bolton Wrinkle Scale (FBWS)</measure>
    <time_frame>Baseline through Month 6</time_frame>
    <description>Fabi-Bolton Wrinkle Scale (FBWS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Assessment-Investigator Percent Improvement Evaluation</measure>
    <time_frame>1, 3, and 6 months</time_frame>
    <description>Investigator Percent Improvement Evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Assessment-Investigator Global aesthetic improvement scale (I-GAIS)</measure>
    <time_frame>1, 3, and 6 months</time_frame>
    <description>Investigator Global aesthetic improvement scale (I-GAIS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Assessments-Subject Global aesthetic improvement scale (S-GAIS)</measure>
    <time_frame>1, 3, and 6 months</time_frame>
    <description>Subject Global aesthetic improvement scale (S-GAIS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Assessments-Patient satisfaction score</measure>
    <time_frame>1, 3, and 6 months</time_frame>
    <description>Patient satisfaction score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Assessments-End of study patient questionnaire</measure>
    <time_frame>Month 6</time_frame>
    <description>End of study patient questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Photodamaged Skin</condition>
  <condition>Photoaging</condition>
  <arm_group>
    <arm_group_label>Altreno</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tretinoin 0.05% lotion (Altreno)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Vehicle lotion not containing tretinoin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tretinoin 0.05% lotion (Altreno)</intervention_name>
    <description>Altreno topical lotion</description>
    <arm_group_label>Altreno</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Lotion not containing active ingredient (tretinoin)</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Females or males age 18-65, Fitzpatrick skin types I-VI&#xD;
&#xD;
          2. Moderate to severe photodamage (Fitzpatrick Wrinkle score of 4-9)&#xD;
&#xD;
          3. Willingness and ability to provide written informed consent and HIPAA authorization&#xD;
             prior to performance of any study-related procedures.&#xD;
&#xD;
          4. Willingness to abstain from any other procedures to the areas to be treated throughout&#xD;
             the trial period.&#xD;
&#xD;
          5. Willingness and ability to comply with protocol requirements, including adherence to&#xD;
             photography and returning for follow-up visits.&#xD;
&#xD;
          6. Women of childbearing potential willing to use an acceptable form of birth control&#xD;
             during trial period.&#xD;
&#xD;
               1. Hormonal contraception - pill, injection, implant, patch, vaginal ring,&#xD;
                  Intrauterine device&#xD;
&#xD;
               2. Intrauterine coil&#xD;
&#xD;
               3. Barrier method used with an additional form of contraception (e.g., sponge,&#xD;
                  spermicide or condom)&#xD;
&#xD;
               4. Abstinence (If practicing abstinence must agree to use barrier method described&#xD;
                  above (c) if becomes sexually active).&#xD;
&#xD;
               5. Vasectomized partner (Must agree to use barrier method described above (c) if&#xD;
                  becomes sexually active with an Un-Vasectomized partner).&#xD;
&#xD;
          7. Female patients will be either of non-childbearing potential defined as: Having no&#xD;
             uterus and/or both ovaries, postmenopausal (no menses for at least 12 months prior),&#xD;
             or has had a bilateral tubal ligation at least 6 months prior to study enrollment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy, currently breast feeding or planning pregnancy for the duration of the&#xD;
             trial.&#xD;
&#xD;
          2. Known hypersensitivity or allergy to the components of the study medication.&#xD;
&#xD;
          3. Concurrent enrollment in any study involving the use of investigational devices or&#xD;
             drugs.&#xD;
&#xD;
          4. Current smoker or history of smoking in the last five years.&#xD;
&#xD;
          5. Current user of any nicotine-containing products, e.g., e-cigarettes, Nicorette gum,&#xD;
             nicotine patches, etc.&#xD;
&#xD;
          6. Presence of an active systemic or local skin disease that may affect treatment area.&#xD;
&#xD;
          7. History of prior surgery to the treatment area&#xD;
&#xD;
          8. History of prior significant trauma to the chest&#xD;
&#xD;
          9. History of the following cosmetic treatments to the area(s) to be treated:&#xD;
&#xD;
               1. Energy based device or laser procedure to the chest within the past 6 months&#xD;
                  (Ultherapy, ablative and non-ablative laser, intense pulsed light, etc)&#xD;
&#xD;
               2. Injectable filler of any type to the chest in the past 2 years (Hyaluronic acid&#xD;
                  fillers (Voluma, Belotero), Poly-L-Lactic acid fillers (e.g. Sculptra), and CaHA&#xD;
                  fillers (e.g. Radiesse)&#xD;
&#xD;
               3. Ever for permanent fillers (e.g. Silicone, ArteFill)&#xD;
&#xD;
         10. Surgical dermabrasion or chemical peels in the treatment area within the past 6 month&#xD;
&#xD;
         11. Any planned surgical intervention to the chest for the duration of the trial&#xD;
&#xD;
         12. Any visible surface alteration to the chest that may interfere with evaluation, at&#xD;
             investigator discretion&#xD;
&#xD;
         13. Any pre-existing medical condition that may interfere with study compliance or&#xD;
             evaluation, at investigator discretion&#xD;
&#xD;
         14. Inability to comply with all study protocols and regulations&#xD;
&#xD;
         15. Current taking an immunosuppressant or applying a topical corticosteroid to the&#xD;
             affected area&#xD;
&#xD;
         16. Unwilling to minimize exposure to sunlight and sunlamps during the course of the&#xD;
             study.&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sabrina Fabi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cosmetic Laser Dermatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cosmetic Laser Dermatology/West Dermatology Research Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 18, 2019</study_first_submitted>
  <study_first_submitted_qc>September 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2019</study_first_posted>
  <last_update_submitted>April 1, 2021</last_update_submitted>
  <last_update_submitted_qc>April 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Skin</keyword>
  <keyword>Chest</keyword>
  <keyword>Photodamage</keyword>
  <keyword>Sun Damage</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tretinoin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

